TITLE

Cistitis aguda en mujeres con diabetes mellitus tipo 2

AUTHOR(S)
López-Carmona, Juan Manuel; Salazar-López, María Alejandra; Rodríguez-Moctezuma, José Raymundo; López-Delgado, María Elisa; Manrique-Lizárraga, Juana María
PUB. DATE
September 2007
SOURCE
Revista Medica del IMSS;sep/oct2007, Vol. 45 Issue 5, p503
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Objective: To compare the effectiveness and secondary effects of trimethoprim-sulfamethoxazole (TMP-SMX), ciprofloxacin, and nitrofurantoin in women with type 2 diabetes mellitus (DM2) and acute community-acquired cystitis. Methods: A randomized single blind clinical trial was conducted in the family medicine clinic No. 91 of Instituto Mexicano del Seguro Social in Coacalco, Mexico. The study included women with DM2 and acute cystitis who were randomly allocated to one of the following schemes: TMP-SMX (160/ 800 mg every 12 h), ciprofloxacin (500 mg every 12 h) or nitrofurantoin (100 mg every 6 h) for 10 days. Results: Sixty-one patients fulfilled the inclusion criteria. Bacteriologic eradication at the end of the treatment was observed in 18/23 (78 %) of patients treated with ciprofloxacin; 14/18 (78%) of patients treated with nitrofurantoin; and 9/20 (45 %) of patients treated with TMP-SMX (p = .036). The difference between nitrofurantoin and TMP-SMX, as well as between ciprofloxacin with TMPSMX, was 33 % for both (95 % confidence interval = 4 %, 62 %, and 5 %, 61 % respectively). The most frequently isolated bacterium was Escherichia coli (75 %), The in vitro resistance rate to TMP-SMX was 76 %, to ciprofloxacin 17 % and to nitrofurantoin 13 % (p = 0.05). The main adverse effects were slight to moderate headache, nausea, and pyrosis in the three groups. Conclusions: ciprofloxacin and nitrofurantoin were more effective than TMP-SMX for the treatment of community-acquired acute cystitis in Mexican women with DM2. This is probably due to differences in the resistance rates and is probably not specific for diabetic patients; All three antimicrobials were safe.
ACCESSION #
28122242

 

Related Articles

  • NITROFURANTOIN AND COTRIMOXAZOLE IN THE EXTENDED THERAPY OF URINARY TRACT INFECTIONS IN TYPE 2 DIABETIC WOMEN. MOŻDŻAN, MONIKA; MOŻDŻAN, MICHAL; RUXER, JAN; BAŁA, AGNIESZKA; BRONCEL, MARLENA // Problemy Terapii Monitorowanej;dic2008, Vol. 19 Issue 4, p289 

    Purpose. The aim of this study was to evaluate the efficacy of nitrofurantoin and cotrimoxazole in the treatment of recurrent, uncomplicated lower urinary tract infections (RUTIs) in type 2 diabetic women. Materials and methods. Including criteria were as followed: post-menopaused females aged...

  • Cotrimoxazole/rosiglitazone/glimepiride interaction.  // Reactions Weekly;6/28/2008, Issue 1208, p11 

    The article describes the case of a 56-year-old woman who developed hypoglycemia after receiving cotrimoxazole in addition to her rosiglitazone/glimepiride treatment regimen for type 2 diabetes mellitus. The patient was given cotrimoxazole for an abscess on her buttock. Days after receiving...

  • Emphysematous cystitis. Lee, Eun-Young // QJM: An International Journal of Medicine;Jul2013, Vol. 106 Issue 7, p685 

    No abstract available.

  • Demographic, Clinical, and Treatment Parameters Influencing the Outcome of Acute Cystitis. Echols, Rogert M.; Tosiello, Robert L.; Haverstock, Daniel C.; Tice, Alan D. // Clinical Infectious Diseases;7/1/99, Vol. 29 Issue 1, p113 

    Focuses on a study which determined the effects of ciprofloxacin, ofloxacin, norfloxacin, trimethoprim-sulfamethoxazole for the treatment of acute cystitis. How the study was conducted; Prognostic factors for bacteriologic response; Frequency of pyuria before therapy stratified by colony count...

  • Vildagliptin: profile report. Mueller, Tanja; Barkun, Alan N // Drugs & Therapy Perspectives;Mar2007, Vol. 23 Issue 3, p4 

    Adapted and reproduced from Drugs 2006; 66 (15): 1989-2004[1-4]

  • Rimonabant: An Answer to Obesity in Diabetes? Kuritzky, Louis // Internal Medicine Alert;1/15/2007, Vol. 29 Issue 1, p7 

    The article discusses research being done on the effectiveness of rimonabant for obese patients with type 2 diabetes.

  • OPTIMUS-3: Prasugrel bested off-label doses of clopidogrel in small population of patients with type 2 diabetes. Raible, Eric; Rusk, Judy; Southall, Jennifer // Hem/Onc Today;12/10/2009, Vol. 10 Issue 23, p43 

    The article discusses research on the efficacy of a 60-milligram (mg) loading dose and 10-mg maintenance dose of prasugrel against a 600-mg loading dose and 150-mg maintenance dose of clopidogrel in patients with type 2 diabetes and coronary artery disease, presented by Dominick Angiolillo at...

  • Gender and the capacity of women with NIDDM to implement medical advice. Hepworth, Julie // Scandinavian Journal of Public Health;12/31/99, Vol. 27 Issue 4, p260 

    This qualitative study of women with non-insulin dependent diabetes mellitus (NIDDM) examined constructions of their diabetes management and socio-familial relationships as potential sources of support. Semi-structured interview data was collected from 16 women. The transcripts were analysed...

  • Diabetes, milky serum and abdominal pain. Spitzer, Matthew; Brahler, Thomas; Lee, Stephanie L. // Endocrine Today;Nov2011, Vol. 9 Issue 11, p14 

    The article discusses the clinical case of a 43-year-old woman diagnosed with type 2 diabetes mellitus, including the treatment administered to her.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics